MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ
0.6700
-0.0194
-2.81%
After Hours: 0.6700 0 0.00% 19:57 05/09 EDT
OPEN
0.7157
PREV CLOSE
0.6894
HIGH
0.7350
LOW
0.6518
VOLUME
3.85M
TURNOVER
--
52 WEEK HIGH
2.060
52 WEEK LOW
0.5150
MARKET CAP
195.66M
P/E (TTM)
-3.3584
1D
5D
1M
3M
1Y
5Y
1D
Ocugen’s Strategic Advancements and Potential Milestones: A Buy Rating Analysis
TipRanks · 12h ago
Ocugen’s Q1 2025: Progress in Gene Therapy Trials
TipRanks · 1d ago
Ocugen Inc’s Earnings Call: Optimism Amid Financial Challenges
TipRanks · 1d ago
Ocugen Inc. Stock Slips 2.8%, Underperforms Market
Dow Jones · 1d ago
OCUGEN, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025
Press release · 1d ago
Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track
Seeking Alpha · 1d ago
Ocugen Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 1d ago
Ocugen Q1 EPS $(0.05) Beats $(0.06) Estimate, Sales $1.48M Up From $1.01M YoY
Benzinga · 1d ago
More
About OCGN
More
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Recently
Symbol
Price
%Change
    WY
  • 26.21
  • +1.04%

Webull offers Ocugen Inc stock information, including NASDAQ: OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.